Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy

Tanja Obradovic shared on LinkedIn:

“Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy are certain to be raised even more after announcement today that Phase 3 KeyVibe-010 study will be discontinued due to futility.

Study tested Vibostolimab and Pembrolizumab co-formulation as an adjuvant treatment in resected high-risk melanoma patients vs Pembrolizumab monotherapy standard of care.

Patients did not tolerate well co-formulated mix and higher discontinuation rate in the co-formulation arm prevented achievement of statistical significance for the primary endpoint of recurrence-free survival (RFS).

Numerous large Pharma and Biotech companies have invested heavily in TIGIT clinical pipeline but results so far have been mixed with major updates still pending.”